Market Trends of Fill Finish Manufacturing Industry
The Vials Segment is Expected to Hold a Major Share in the Market During the Forecast Period
Vials are typically used to store medicines or laboratory samples. They have various capacities for filling the medicine and can be used as single-dose and multidose vials. The increasing investments of government and market players in fill finish manufacturing using vails are expected to impact the market significantly.
For instance, in February 2024, National Resilience Inc. (Resilience), a biomanufacturing firm with a strong technological focus, broadened its clinical and commercial drug product manufacturing capabilities throughout its network. Currently, the site boasts three high-speed fill lines for vials and others, with a fourth line set to be operational by 2025. Similarly, in January 2022, Recipharm collaborated with the Kingdom of Morocco to construct the largest fill and finish lines dedicated to producing vials in Africa. Hence, market players' new investments expand the facilities for the segment and likely propel the market to grow.
Also, the new company activities in the segment are expected to impact the market significantly. For instance, in November 2022, Berkshire Sterile Manufacturing (BSM) revealed its new, fully automated, 100% isolator-based filling line in a webinar. It can process up to 60,000 units of vials (RTU or bulk), and it has a lyophilization capacity of up to 35,000 10R vials per run. Thus, the new company activity in this segment increases the capacity of the fill finish facilities, which is expected to propel the market during the forecast period.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America is expected to hold a significant market share in the fill finish manufacturing market due to the large production capacities of several pharmaceutical and biopharmaceutical companies in this region. Also, the growing emphasis on superior biopharmaceutical products, the emergence of the biosimilar market, and the patent expiry of biologic products are fueling the growth of the overall regional market.
For instance, in March 2022, Curia, previously known as AMRI, forged a cooperative agreement with the Biomedical Advanced Research and Development Authority (BARDA) and the United States Army Contracting Command. The aim is to bolster the domestic production of injectable medicines. As part of this agreement, funding was allocated to introduce an isolated high-speed fill finish vial line equipped with biosafety level 2 (BSL-2) containment at Curia’s established facility in Albuquerque, New Mexico. This helps in domestic fill finish production of drugs, thereby boosting the market growth in the region.
Similarly, in April 2023, PCI Pharma Services (PCI) stated that three new state-of-the-art automated sterile-fill finish machines at its San Diego facility are fully operational. The innovative machinery from Cytiva can be used to fill various sterile medications into vials and syringes for small-to-mid-scale client needs. These new establishments and agreements among the major players help expand the fill finish facilities and are expected to impact the market significantly during the forecast period.
